Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

892 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
Gibson CM, Duffy D, Korjian S, Bahit MC, Chi G, Alexander JH, Lincoff AM, Heise M, Tricoci P, Deckelbaum LI, Mears SJ, Nicolau JC, Lopes RD, Merkely B, Lewis BS, Cornel JH, Trebacz J, Parkhomenko A, Libby P, Sacks FM, Povsic TJ, Bonaca M, Goodman SG, Bhatt DL, Tendera M, Steg PG, Ridker PM, Aylward P, Kastelein JJP, Bode C, Mahaffey KW, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA; AEGIS-II Committees and Investigators. Gibson CM, et al. Among authors: kastelein jjp. N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2400969. Online ahead of print. N Engl J Med. 2024. PMID: 38587254
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk; Cholesterol Treatment Trialists’ (CTT) Collaboration. Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk, et al. Lancet Diabetes Endocrinol. 2024 May;12(5):306-319. doi: 10.1016/S2213-8587(24)00040-8. Epub 2024 Mar 27. Lancet Diabetes Endocrinol. 2024. PMID: 38554713
Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
Bhatt DL, Bays HE, Miller M, Cain JE 3rd, Wasilewska K, Andrawis NS, Parli T, Feng S, Sterling L, Tseng L, Hartsfield CL, Agollah GD, Mansbach H, Kastelein JJP; ENTRIGUE Principal Investigators. Bhatt DL, et al. Among authors: kastelein jjp. Nat Med. 2024 Mar 4. doi: 10.1038/s41591-024-02890-2. Online ahead of print. Nat Med. 2024. PMID: 38438737 No abstract available.
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Armitage J, Gray A, Simes J, Baigent C, Mihaylova B; CTT Collaboration secretariat; Armitage J, Baigent C, Barnes E, Blackwell L, Collins R, Davies K, Emberson J, Fulcher J, Halls H, Herrington WG, Holland L, Keech A, Kirby A, Mihaylova B, O'Connell R, Preiss D, Reith C, Simes J, Wilson K; CTT Collaboration trialists: A to Z trial (phase Z); Blazing M, Braunwald E, Lemos J, Murphy S, Pedersen TR, Pfeffer M, White H, Wiviott S; AFCAPS/TEXCAPS (AirForce/Texas Coronary Atherosclerosis Prevention Study); Clearfield M, Downs JR, Gotto A Jr, Weis S; ALERT (Assessment of Lescol in Renal Transplantation); Fellström B, Holdaas H, Jardine A, Pedersen TR; ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial); Gordon D, Davis B, Furberg C, Grimm R, Pressel S, Probstfield JL, Rahman M, Simpson L; ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events); Koren M; ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial); Dahlöf B, Gupta A, Poulter N, Sever P, Wedel H; ASPEN (Atorvastatin Study for the Prevention of Coronary Heart Disease Endpoints in Non-Insulin Dependent Diabe… See abstract for full author list ➔ Wu R, et al. Among authors: kastelein jj. Br J Gen Pract. 2024 Feb 19;74(740):e189-98. doi: 10.3399/BJGP.2023.0198. Online ahead of print. Br J Gen Pract. 2024. PMID: 38373851 Free PMC article.
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.
Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH. Kastelein JJP, et al. Curr Atheroscler Rep. 2024 Feb;26(2):35-44. doi: 10.1007/s11883-023-01184-1. Epub 2023 Dec 22. Curr Atheroscler Rep. 2024. PMID: 38133847 Free PMC article. Review.
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment.
Santos RD, Ruzza A, Wang B, Maruff P, Schembri A, Bhatia AK, Mach F, Bergeron J, Gaudet I, St Pierre J, Kastelein JJP, Hovingh GK, Wiegman A, Gaudet D, Raal FJ. Santos RD, et al. Among authors: kastelein jjp. Eur J Prev Cardiol. 2024 Feb 15;31(3):302-310. doi: 10.1093/eurjpc/zwad332. Eur J Prev Cardiol. 2024. PMID: 37855448 Clinical Trial.
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, Kastelein JJP; ORION-5 Study Investigators. Raal F, et al. Among authors: kastelein jjp. Circulation. 2024 Jan 30;149(5):354-362. doi: 10.1161/CIRCULATIONAHA.122.063460. Epub 2023 Oct 18. Circulation. 2024. PMID: 37850379 Free PMC article. Clinical Trial.
892 results